Original Research Article

A randomized trial of Honey versus Povidone Iodine Dressings: Pain profile of Wagner Grade 2 Diabetic Foot Ulcers

UNDER PEER REVIEW

ABSTRACT

Diabetic foot ulcers (DFU), a chronic disorder of public health importance arises from pathologic changes following abnormal glucose metabolism. Wound dressing is vital to DFU management and is designed to promote healing and relieve pain among other roles. Pain associated with chronic wounds can delay healing, reduce quality of life and affect mental health.
This study aimed to evaluate the effect of honey and povidone iodine based dressings on the severity of pain associated with Wagner grade 2 DFU.

Study design: This was a randomizedcontrolled trial on the pain modulating effects of honey and povidone iodine dressings on Wagner grade 2 DFUusing the visual analogue scale(VAS) at the University of Port Harcourt Teaching Hospital(UPTH), Port Harcourt over one-year duration.

Methodology: We included 30 patients (17 males, 13 females; age range 47-65 years) with Wagner grade 2 diabetic foot ulcers. Data on socio-demographics and Visual analogue scale scores (VAS) for assessing pain intensity were obtained serially and analyzed using Statistical Package for the Social Sciences (SPSS) 20.0. A p-value <0.05 was considered significant**.**

Results: The median VAS pain score was 2.0 and 3.0 for the honey and povidone iodine dressing groups respectively (p-value=0.724) in week 1, then 1.0 and 2.0 for the honey and povidone iodine dressing groups respectively and (p-value=0.041) in week 3.

Conclusion: Honey dressings are associated with less wound pain over the course of treatment compared to povidone iodine dressing in the treatment of Wagner 2 DFU.

Keywords: Diabetic ulcer, dressing, povidone-iodine, honey, wound pain, visual analogue scale, public health

1. INTRODUCTION

Diabetes mellitus (DM) is a metabolic disorder with public health implications that results from absolute or relative deficiency in insulin action or secretion, leading to impaired glucose metabolism and fasting hyperglycemia of ≥7.0mmol/L.[1,2] The interaction between genetics and environmental factors such as diet, is pivotal to the pathophysiologic changes in multiple organ systems which increase morbidity including limb and ulcer pain, lower quality of life, and eventually causes death if glycemic control remains poor, as observed in nearly 10% of medical deaths.[1-3]

The global DM prevalence among those aged 20-79 years is projected to rise to 8.5-13.5% (521-829 million people) by 2040. [4,5] The prevalence is 5-7% in urban sub-Saharan Africa, and 4-10% in Nigeria. [6,7]

Diabetic foot ulcers (DFU) arise from the interplay between angiopathy neuropathy, and reduced immunity which produces infection, ulceration, and gangrene.[4,8,9] Impaired glucose metabolism leads to sorbitol and fructose accumulation (polyol pathway), ultimately causing peripheral nerve damage.[2,8] Advanced glycation end-products deposited in tissues cause multiple organ dysfunction, accelerated atherosclerosis, delayed growth of collateral vessels, and thrombosis.[2] Autonomic dysfunction causes anhydrosis, dry, easy-cracking skins that allow bacterial invasion, and ulcer formation. [8] Also, impaired bacterial phagocytosis and reduced cell-mediated immunity promotes polymicrobial infection. [1,8,10]

In Nigeria, the prevalence of DM foot lesions is 0.9- 8.3% and rising. [11-13] Over 15% of diabetics develop DFU in their life time, associated with physical, psychological and economic disability. [3,11,12,14] DFU bring about over 80% of non-traumatic, lower limb amputations with attendant life altering sequelae particularly in resource-limited settings. [3,4,11]

Multidisciplinary management focused on patient education, good glycaemic control, regular foot examinations (including sensory assessment with a 10-g monofilament, standard (128 Hz) tuning fork and a reflex hammer), and aggressive intervention (debridement, antibiotic therapy, regular dressing) are fundamental to the care of the diabetic foot. [2,12,14,15] Good glycaemic control lowers the risk of neuropathy by 40-60%. [3]

In addition to providing physical and antimicrobial protection, wound dressings should reduce pain, provide a moist environment, absorb exudates, control odour, and be inexpensive. [8,16,17,18]. There is yet no perfect dressing for DFU. [16] The wound characteristics i.e. appearance and exudate, guide the choice of dressing. [19-21]

The therapeutic use of honey spans centuries. [10,16] Honey is a supersaturated sugar solution made by bees, from nectar or other plant fluids. [22,23] It contains 80–85% carbohydrate (mostly glucose and fructose), 15–17% water, 0.1–0.4% protein, 0.2% ash, amino acids, vitamins and phenolic antioxidants.[23-25] Its hydrogen peroxide, inhibin, and high acidity(pH 3.2-4.2) inhibit bacterial proliferation.[10,24,26,27] It reduces inflammation, debrides necrotic tissues, enhances granulation tissue, deodorizes infected wounds, reduces pain, promotes epithelization and minimizes scarring when used topically.[10,26,28] Its soothing effect is attributed largely to its capacity to conserve moisture, prevent adherence to wound beds, and preserve nascent granulation tissue and keratinocytes during change of dressing. [11, 26]

Povidone-iodine is a loose mixture of iodine and a non-ionic surfactant. [29,30] Its antimicrobial activity is maximal at 0.1%–1% (after dilution) due to the weakened link between the carrier polymer and iodine molecules, leading to the increased amount of elemental “free” iodine in solution. [16,29] Despite its widespread use, acquired resistance to it remains rare. [9,29]

Several DFU classification systems exist. [14,31] However, the Wagner classification which considers the ulcer depth, presence of osteomyelitis, and amount of tissue gangrene, is most widely utilized. [14] Wagner Grade 2 ulcers are deep ulcers to tendon, bone, ligament, or joint involvement. [9,14]

The study of ulcer and limb pain is generating renewed public heath interest. [32] Data from the psychological assessment of persons with chronic pain indicate high rates of psychopathology, amplified by pathologic wound exudate and odor, along with actual and perceived discrimination and social isolation. [32,33] Clinically substantial anxiety or depression was found in 30–35% of inpatients suffering from pain. [32] Hence the growing relevance of pain assessment tools like the visual analogue scale(VAS), verbal rating scale (VRS), and short form-brief pain inventory (SF-BPI), and the inclusion of professionals in the hospital and community settings in the care of these persons. [34]

The VAS, a psychometric response scale is used to indirectly measure subjective parameters such as pain, indicating a spot along a continuous line between two end-points (0 to 100mm apart) which represent the extremes of the character being assessed. It is often considered the gold standard in pain research. [35] About 95.2% of subjects were found to be capable of reading the VAS in concordance with a physician reading, with a precision error of ±2mm. [36]

2. METHODOLOGY

2.1 Study Design

UNDER PEER REVIEW

This was a randomized controlled trial comparing ulcer pain following honey and povidone iodine dressing among patients with Wagner grade 2 DFU who presented to the UPTH via the orthopedic clinic and medical wards between April 1st 2017 and April 30th, 2018.

2.2 Sample Size Determination

Sample size for the study was calculated using the formula for comparison of groups **[**37]

$$n = \frac{2\,(Z\alpha + Z\beta)^2 s^2}{d^2}$$

n = minimum sample size

$Z\alpha$ = significance level of 95%; corresponds to a value of 1.96

$Z\beta$ = power of 80%; corresponds to a value of 0.84

S = standard deviation; standard deviation of the rate of healing among patients with diabetic foot ulcers using honey dressing from a similar study was 0.94. [38]

d = level of precision of 0.5

$$n = \frac{2\,(1.96 + 0.84)^2\,(0.94)^2}{(0.5)^2} = \frac{2\,(7.84)\,(0.884)}{0.025}$$

n= 55.41

Allowance for an attrition of about 10%, the sample size was rounded up to 60.

Adjustment for population <10,000 using finite population correction [37]

$$\text{Adjusted sample size} = \frac{n_0 N}{n_0 + (N-1)}$$

n_0 = minimum sample size = 60

N = Total population of DFU from the review of records (UPTH, 2016) = 47

$$\text{Adjusted sample size} = \frac{60 \times 47}{60 + (47-1)} = 26.6 \text{ approximated to } 30$$

Hence, a total sample size of 30 comprising of 15 patients per group were involved in the study.

2.3 Eligibility Criteria

The subjects were diabetics aged between 30-65 years (lower risk of co-morbidities) with Wagner Grade 2 foot ulcers.

2.3.1 Inclusion Criteria

They also met the following criteria:

a. Ankle brachial pressure index (ABPI) >0.9,
b. Oxygen saturation of ≥92% by pulse oximetry
c. Serum albumin concentration >35g/dl.

2.3.2 Exclusion Criteria

The following subjects were excluded from the study.

a. Patients with multiple co-morbidities, severe immunosuppression, malignant disease or chemotherapy, haemoglobinopathies, steroid therapy and neutrophil count below 2000/mm^3.

UNDER PEER REVIEW

2.4 Study Procedure

2.4.1 Randomization

All subjects who consented to the study and met the inclusion criteria were randomized into two groups; Group A (honey group) and Group B (povidone iodine group) using an opaque envelope containing papers labelled either A or B. A paper was randomly drawn from the envelop for each eligible subject, who was assigned to the group label on the paper.

2.4.2 Blinding

The author was blinded to the dressing for both groups to avoid bias. He was absent at the removal of old dressings, returned to assess the study parameters, and left prior to the new dressings by trained nurses.

2.4.3 Details of the Study

Written informed consent was obtained from each patient. Honey obtained from a single local source while povidone iodine solution 10% was used in the control dressing group. All subjects received appropriate antibiotics and had surgical debridement by the researcher or trained orthopedic residents. Glycemic control was maintained by a supervising physician.

Wound dressing was commenced immediately, and performed daily by trained nurses. The wound was first cleansed with normal saline, and dressed with honey or povidone iodine soaked gauze, supported by layers of dry sterile gauze, and then bandaged.

A weekly wound and pain VAS assessment was performed prior to the change of dressing to avoid bias from the discomfort of the change of dressing. The assessment ended 6 weeks after the initial surgical debridement or when the wound had healed, whichever came earlier.
The consumables used include natural honey, 10% povidone iodine (Betadine®), normal saline, sterile cotton swabs, sterile gauze, crepe bandages, sterile gloves and VAS instrument.

2.5 Data Analysis

Data analysis used the IBM ® Statistical Package for the Social Sciences (SPSS) version 20, and presented as tables and charts. Qualitative variables were stated as frequencies and proportions while quantitative variables such as HbA1c were summarized as means ± standard deviation. Medians and ranges were used to summarize the VAS pain scores. The data were tested for normality by Kolmogorov-Smirnov test prior to analysis. For data with normal distribution (e.g. HbA1c), the differences in means between the groups were compared using the student's t test, while the Mann-Whitney U test was used to compare differences across the VAS pain score. Chi square test or Fisher's exact test was used to compare the differences in proportions between the groups. A p value < 0.05 was considered statistically significant.

3. RESULTS

There were 17 males and 13 females (ratio 1.3:1). The honey group had 7 (46.7%) females, while the povidone iodine group had 9 (60.0%) males. The subjects were aged 47 to 65 years with mean 55.53±5.041 years for group A, and 54.93±5.298 years in group B(t=0.318; p-value=0.753). The 55-59 years age group (40%) had the highest frequency. The difference in the age (p-value=0.266) and sex (p-value=0.713) distribution was not significant.

Most study participants were overweight (63.3%). The difference in proportions of BMI category between both groups was not statistically significant (p-value=0.762). The mean BMI were 27.34±2.783 kg/m2 and 27.99±2.336 kg/m2 in the honey and povidone dressing groups respectively (p-value=0.492).

Erectile dysfunction was the commonest DM complication encountered in the povidone iodine group (53.3%), while visual impairment was the most frequent in the honey group (53.3%). One patient had a prior history of a foot ulcer in each study group (6.7%).

UNDER PEER REVIEW

Figure 1: Distribution of complications of diabetes mellitus



In the honey group, 46.7% of the ulcers resulted from trauma, 46.7% developed spontaneously, and 6.7% had burn injury, while ulcers in the povidone iodine group were caused by trauma (33.3%), tight shoes (13.3%) or developed spontaneously (53.4%). The distribution of ulcer causation between the study groups had no significant statistical difference (p-value=0.536) as shown in Table 1.

Table 1: Distribution of ulcer etiology

	Groups in the study		
	Honey	**Povidone-Iodine**	**Total**
Ulcer etiology	**n (%)**	**n (%)**	**n (%)**
Burn	1 (6.7)	0 (0.0)	1 (3.3)
Trauma	7 (46.7)	5 (33.3)	12 (40.0)
Tight shoe	0 (0.0)	2 (13.3)	2 (6.7)
Spontaneous	7 (46.7)	8 (53.4)	15 (50.0)
Total	**15 (100.0)**	**15 (100.0)**	**30 (100.0)**

Fisher's exact test=2.992; p-value=0.536

Left feet were affected by 63.3% of ulcers, while right foot involvement was seen in 36.7% of the study population. The most common site was the dorsum of the left foot (40.0%) as seen in 33% and 46.7% of the honey and povidone groups respectively. The medial aspect of the forefoot and left big toe were the least affected regions (3.3% each). There was no significant difference (p-value=0.392) in the anatomical location between the study groups (Table 2).

Table 2: Distribution of ulcer sites

	Groups in the study		
	Honey	**Povidone-Iodine**	**Total**
Ulcer site	**n (%)**	**n (%)**	**n (%)**

UNDER PEER REVIEW

Left big toe	1 (6.7)	0 (0.0)	1 (3.3)
Left dorsum	5 (33.3)	7 (46.7)	12 (40.0)
Left heel	2 (13.3)	0 (0.0)	2 (6.7)
Left sole	1 (6.7)	2 (13.3)	3 (10.0)
Left medial forefoot	0 (0.0)	1 (6.7)	1 (3.3)
Right Dorsum	1 (6.7)	2 (13.3)	3 (10.0)
Right heel	3 (20.0)	0 (0.0)	3 (10.0)
Right sole	2 (13.3)	3 (20.0)	5 (16.7)
Total	**15 (100.0)**	**15 (100.0)**	**30 (100.0)**

Fisher's exact test=7.527; p-value=0.392

The duration between the development of foot ulcers and the initial debridement ranged from 5-15 days, giving mean values of 8.53±4.533 days and 7.73±2.374 days for the honey and povidone iodine groups respectively. This difference was not statistically significant (p-value=0.550).

The subjects' HbA1c values ranged from 6.3% - 10.2% (mean: 7.40±0.944%) in the povidone iodine group, and 6.7%-9.9% (mean: 7.52±1.023%) for the honey group. This difference in was not statistically significant (p-value=0.727).

None of the respondents in both groups achieved complete wound healing in the first three weeks of follow-up. By week 4, 11(73.3%) and 6 (60.0%) had complete wound healing in honey and povidone iodine groups respectively. By week 5, all diabetic patients in honey group had complete wound healing while all but one of the patients in the povidone-iodine group had complete wound healing. The remaining lone DFU persisted till the end of the study period in week 6 as shown in Figure 2.

PEER REVIEW

Figure 2: Distribution of wound healing across the time period



In the first week, serosanguinous exudates were seen in 66.7% and 60% of ulcers in the honey and povidone iodine groups respectively, while 6.7% of ulcers in each group had seropurulent exudates. The ulcers with serous exudates made up 26.7% and 33.3% of the honey and povidone iodine groups. By week 2, the ulcers with serous exudates

increased to 66.7% and 73.3% in the honey and povidone iodine groups respectively. However, all exudates turned serous by the third week and remained so until the ulcers were healed or till the end of the study (Table 3).

Table 3: Comparison of wound exudate findings across the study period

	Groups in the study		
	Honey (N=15)	**Povidone iodine (N=15)**	**Total**
Type of exudate	**n (%)**	**n (%)**	**n (%)**
Week 1			
Seropurulent	1 (6.7)	1 (6.7)	2 (6.7)
Serosanguinous	10 (66.7)	9 (60.0)	19 (63.3)
Serous	4 (26.7)	5 (33.3)	9 (30.0)
Week 2			
Serosanguinous	5 (33.3)	4 (26.7)	9 (30.0)
Serous	10 (66.7)	11 (73.3)	21 (70.0)
Week 3			
Serous	15 (100.0)	15 (100.0)	30 (100.0)
Week 4			
Serous	4 (26.7)	6 (40.0)	10 (33.3)
Week 5			
Serous	0 (0.0)	1 (6.7)	1 (3.3)
Week 6			
Serous	0 (0.0)	1 (6.7)	1 (3.3)

The median visual analogue scale pain score was 2.0 and 3.0 for the honey and povidone iodine dressing groups respectively (p-value=0.724) in week 1. By week 3, the difference in the median score between the patients in honey group (1.0) and povidone iodine group (2.0) was statistically significant (p-value=0.041) as shown in Table 4.

Table 4: Comparison of median pain scores (Visual Analogue Scale) across the study groups

	Groups in the Study			
Time of follow-up	**Honey Median VAS (Range)**	**Povidone Iodine Median VAS (Range)**	**Mann-Whitney U**	**p-value**

UNDER PEER REVIEW

Week one	2.0 (1-4)	3.0 (1-4)	104.50	0.724
Week two	2.0 (1-3)	2.0 (1-3)	103.00	0.663
Week three	1.0 (1-3)	2.0 (1-3)	68.50	0.041*
Week four	1.0 (1-1)	1.0 (1-2)	8.00	0.221
Week five	-	2.0 (2-2)	-	-
Week six	-	1.0 (1-1)	-	-

*Statistically significant

UNDER PEER REVIEW

Figure 3 shows the mean pain scores in honey and povidone iodine groups across the follow-up period. Other than Week 1, the pain scores were lower in the honey group in comparison to the povidone iodine group.

Figure 3: Comparison of the mean VAS scores across the follow-up period



4. DISCUSSION

The burden of DM and its complications, especially DFU is emphasized by the difficulty faced while seeking patients who met the inclusion criteria, patients expected to be as healthy as possible, since most diabetics already have complications at the onset of foot ulceration. [13,39,40]

This study found that data on demographics, BMI, HbA1c level, and ulcer aetiology, location, and ulcer duration prior to presentation, of both the honey and povidone iodine groups were comparable. The similarity in mean HbA1c between both study groups (p-value=0.727) eliminates HbA1c level as a possible confounding factor especially in relation to neuropathy. [41]

Erectile dysfunction occurred in 88% of the male subjects. However, other causes of erectile dysfunction such as anxiety and drugs such as beta-blockers [42] were not ruled out. Visual impairment, paraesthesia and decreased libido were also reported. In a Tanzanian study, [43] 10.3% of subjects had previous DFU, while Unachukwu *et al* [44] reported a 33% history of previous ulcers among patients with all grades of DFU. More divergently, Ngwogu *et al.*, noted a 10.6%, and 9.2% incidence of peripheral neuropathy and DFU respectively in their study. [2]

While 50% of the index ulcers developed spontaneously; trauma, tight shoes and burn injury constituted 40%, 6.7% and 3.3% respectively. Similarly, Unachukwu *et al* [44] observed a 51.7% incidence of spontaneously occurring ulcers. Khan *et al*in Pakistanreported accidental/foot wear-trauma (36%) and foot deformity (46%). [40]Some of these spontaneous DFU could have resulted from unnoticed (delayed by underlying neuropathy and retinopathy) micro-trauma which became infected. [2, 5,10]

The dorsum of the left foot (40%) was the most common ulcer site in this study in consonance with the observation of Unachukwu *et al*. [44] The reason for this is unclear. Studies show that 70-90% of the world's population are right hand/foot dominant. [45]The non-dominant limb may be relatively less perceptive to micro-trauma which goes unnoticed, leading to ulceration, given the background immunosuppression of DM. [1,5,10] More research is needed on this finding.

The mean duration between the onset of ulcers and the debridement were 8.53±4.533 days and 7.73±2.374 days for the honey and povidone iodine groups respectively. This relatively early presentation suggests good health seeking behaviour which could have been prompted by the health education received at the endocrinology clinic. This may explain the adequacy of their vascular statuses which enabled them to meet the study's inclusion criteria. Also, ignorance and socio-cultural influences may contribute to late presentation. [6] Ogbera *et al*. noted that 78% of their study respondents believed that 'poisoning' and 'curses' were responsible for foot ulcers. [6] People with such perceptions are inclined to seek spiritual help before presenting to the hospital.

The mean healing time of 4.00±0.00 weeks was observed in ulcers in the honey group. Correspondingly, ulcers in the povidone iodine group were healed around 5.00±0.00 weeks. There was no significant difference in the wound healing between the study groups.[13,15]

Initially, 63% of exudates were serosanguinous following debridement. Subsequently, all ulcers in both groups had serous exudates by the third week signifying improved healing. Good exudate is typically serous (clear, pale amber, watery and odourless). [46] Wound exudate have been classified based on quantity as absent(0), small(1), moderate(2), or large(3). [47] This study opted for qualitative assessment because the clinical appearance has more bearing on the presence or otherwise of infection which can worsen pain, while the mere amount of exudate may correlate more with factors that increase capillary leakage such as limb dependency. [46]

The median visual analogue scale pain score was 2.0 and 3.0 for the honey and povidone iodine dressing groups respectively (p-value=0.724) in week 1, then 1.0 and 2.0 for the honey and povidone iodine dressing groups respectively (p-value=0.041) in week 3. This was statistically significant. This is somewhat similar to the findings of Dickinson *et al* [34] who examined the characteristics of pain associated with DFU, and reported an overall median VAS score of 2.0. Mohamed *et al*. [28] and Gulati *et al*., [48] similarly reported significantly reduced VAS pain scores among patients treated with honey dressings compared to povidone iodine dressings. However, in contrast with the study by Dickinson *et al*, no patient in the index study reported 'non-existent' pain. [34] This was probably because their study primarily involved patients with neuropathic and other wound aetiologies who might have had anaesthetic feet/ulcers. The strength of this study is hinged on its design as a RCT to provide substantial evidence on the effect of honey versus povidone iodine on the pain profile of diabetic patients. However, being a single centre study, this could limit the generalizability of the study, therefore multi-centre studies are recommended.

5. CONCLUSION

UNDER PEER REVIEW

Complications occur commonly among diabetic patients, with DFU often developing without obvious causes. Honey dressings are associated with less wound pain over the course of treatment thereby better easing patient discomfort compared to povidone iodine dressings. It is also important to monitor the nature of exudates produced, as they may serve as pointers to on-going events in the ulcers.

CONSENT AND ETHICAL APPROVAL

Ethical approval was obtained from the research and ethics committee of the UPTH prior to the commencement of the study. Written informed consent was obtained from all study participants after beingadequately informed about the nature, extent and purpose of the research. Anonymity and confidentiality were upheld in the study. Participation in the study was voluntary, and patients' withdrawal from the study did not affect their medical care.

REFERENCES

1. Powers AC. Diabetes mellitus. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. Harrison's principles of internal medicine. 18th Edition. New York: McGraw-Hill, 2012:2968-3009.
2. Ngwogu KO, Mba IE, Ngwogu AC. Morbidity pattern of diabetic admissions at the Abia State University Teaching Hospital, Aba, Nigeria. Int J Community Res 2012;1(2):49–53.
3. Igbinovia E. Diabetic foot ulcers: current trends in management. Benin J Postgrad Med 2009;11(1): 130-138.
4. Jain AK. A new classification of diabetic foot complications: a simple and effective teaching tool. J Diabetic Foot Complicat 2012;4(1):1-5.
5. International Diabetes Federation. IDF Diabetes Atlas. 7th Edition. Brussels, Belgium: International Diabetes Federation, 2015.
6. Ogbera AO, Ekpebegh C. Diabetes mellitus in Nigeria: The past, present and future. World J Diabetes 2014; 5(6): 905-11.
7. International Diabetes Federation. IDF Diabetes Atlas, 10th Edition. Brussels, Belgium: 2021. Available at: https://www.diabetesatlas.org
8. Calhoun JH, Mader JT. Diabetic foot care. In: Chapman MW. Chapman's Orthopaedic Surgery. 3rd Edition. Philadelphia: Lippincott Williams & Wilkins, 2001; 3074-3095.
9. Chadwick P, Edmonds M, McCardle J, Armstrong D. Best practice guidelines: wound management in diabetic foot ulcers. London: Wounds International, 2013. Available from www.woundsinternational.com Accessed 25/05/2016.
10. Shukrimi A, Sulaiman AR, Halim AY, Azril A. A comparative study between honey and povidone iodine as dressing solution for Wagner type II diabetic foot ulcers. Med J Malaysia 2008; 63(1): 44-46.
11. Edo AE, Edo GO, Ezeani IU. Risk factors, ulcer grade and management outcome of diabetic foot ulcers in a tropical tertiary care hospital. Niger Med J 2013;54:59-63.
12. Edo AE, Eregie A. Bacteriology of diabetic foot ulcers in Benin City, Nigeria. Diabetes International 2007; 15(1):21-23.
13. Danmusa UM, Terhile I, Nasir IA, Ahmad AA, Muhammad HY. Prevalence and healthcare costs associated with the management of diabetic foot ulcer in patients attending Ahmadu Bello University Teaching Hospital, Nigeria. Int J Health Sci (Qassim) 2016; 10(2): 219-228.
14. Frykberg RG. Diabetic foot ulcers: pathogenesis and management. Am Fam Physician 2002; 66(9) :1655-1662.
15. Rüttermann M, Maier-Hasselmann A, Nink-Grebe B, Burckhardt M. Local treatment of chronic wounds in patients with peripheral vascular disease, chronic venous insufficiency and diabetes. Dtsch Arztebl Int 2013; 110(3):25-31.
16. Hilton JR, Williams DT, Beuker B, Miller DR, Harding KG. Wound dressings in diabetic foot disease. Clin Infect Dis 2004;39 Suppl 2: 100–103.
17. Deodhar AK, Rana RE. Surgical physiology of wound healing: a review. J Postgrad Med 1997;43(2):52-56.
18. Wounds UK Best Practice Statement. Effective exudate management. London: Wounds UK, 2013. Available from www.wounds-uk.com Accessed 08/04/2015.
19. Murphy PS, Evans GR. Advances in wound healing: a review of current wound healing products. Plast Surg Int 2012; 2012:190436.
20. Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care 2008; 31(4):631–636.
21. Game FL, Hinchliffe RJ, Apelqvist J, Armstrong DG, Bakker K, Hartemann A et al. A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev 2012; 28 Suppl 1: 119–141.

UNDER PEER REVIEW

22. Codex Alimentarius Commission. Revised Codex Standard for honey. Codex Standard 12-1981, Rev 1(1987), Rev 2(2001). Rome: FAO/WHO Food Standards Programme, 2001.
23. Buba F, Gidado A, Shugaba A. Analysis of biochemical composition of honey samples from North-East Nigeria. Biochem Anal Biochem 2013; 2(3):139.
24. Fasasi KA. Physicochemical attributes of Nigerian natural honey from honey bees (Apis mellifera adansonii) (Hymenoptera:Apidae) and its shelf life in storage at room temperature. Pak J Biol Sci 2012;15(21):1027-1033.
25. Agbagwa OE, Frank-Peterside N. Effect of raw commercial honeys from Nigeria on selected pathogenic bacteria. Afr J Microbiol Res 2010; 4(16):1801-1803.
26. Mohamed H, Salma MA, Al-Lenjawi B, Abdi S, Gouda Z, Barakat N et al. The efficacy and safety of natural honey on the healing of foot ulcers: a case series. Wounds 2015;27(4):103-14.
27. Rahman MM, Gan SH, Khalil MI. Neurological effects of honey: current and future prospects. Evid Based Complement Alternat Med. 2014; 2014: 958721.
28. Agarwal S, Bhardwaj V, Singh A, Khan MH , Goel S, Bharat M et al. A control clinical trial of honey-impregnated and povidone iodine dressings in the treatment of diabetic foot ulcers among northern Indian subjects. Indian J Sci Res 2015;6(2): 7-10.
29. Schneider LA, Korber A, Grabbe S, Dissemond J. Influence of pH on wound-healing: a new perspective for wound-therapy? *Arch Dermatol Res* 2007;298(9):413-420.
30. Leong M, Phillips LG. Wound Healing. In: Townsend CM, Beauchamp RD, Evers BM, Mattox KL, eds. Sabiston textbook of surgery: the biological basis of modern surgical practice. 19th Edition. Philadelphia: WB Saunders, 2012; 151-177.
31. Kirfel G, Herzog V. Migration of epidermal keratinocytes: mechanisms, regulation, and biological significance. *Protoplasma* 2004; 223(2-4): 67–78.
32. Rockett MP, Simpson G, Crossley R, Blowey S. Characteristics of pain in hospitalized medical patients, surgical patients, and outpatients attending a pain management centre. *Br J Anaesth* 2013; 110(6): 1017–1023.
33. Do Espírito Santo PF, de Almeida SA, Silveira MM, Salomé GM, Ferreira LM. Use of the Pressure Ulcer Scale for Healing tool to evaluate the healing of chronic leg ulcers. *Rev Bras Cir Plást.* 2013;28(1):133-141.
34. Dickinson AM, Frescos N, Firth JC, Hamblin PS. The characteristics of wound pain associated with diabetes-related foot ulcers: a pilot study. *Wound Pract Res* 2016; 24 (3) :138-148.
35. Daoust R, Beaulieu P, Manzini C, Chauny J, Lavigne G. Estimation of pain intensity in emergency medicine: a validation study. Pain 2008; 138(3): 565-570.
36. Salo D, Eget D, Lavery RF, Garner L, Bernstein S, Tandon K. Can patients accurately read visual analog pain scale? Am J Emerg Med 2003;21(7): 515-519.
37. Katz DL, Wild DM, Elmore JG, Lucan SC. Sample size. In: Katz DL, Wild DM, Elmore JG, Lucan SC. Jekel's epidemiology, biostatistics, preventive medicine and public health. 4th Edition. Philadelphia, PA: Saunders/Elsevier. 2014; 155.
38. Moghazy AM, Shams ME, Adly OA, Abbas AH, El-Badawy MA, Elsakka DM, *et al*. The clinical and cost effectiveness of bee honey dressing in the treatment of diabetic foot ulcers. *Diabetes Res Clin Pract* 2010;89(3):276-281.
39. Ekere AU, Yellowe BE, Dodiyi-Manuel A. Pattern and management of diabetic foot disease in a developing country. Niger J Med 2005; 14(3):272-275.
40. Khan H, Khan Z, Khan I, Din J, Rehman S, Khan B. Factors contributing to the development of diabetic foot ulcers and role of health literacy. Rawal Med J 2011; 36(1):34-37
41. Christman AL, Selvin E, Margolis DJ, Lazarus GS, Garza LA. Hemoglobin A1c predicts healing rate in diabetic wounds. *J Invest Dermatol* 2011;131(10): 2121–2127.
42. Mobley DF, Khera M, Baum N. Recent advances in the treatment of erectile dysfunction. *Postgrad Med J* 2017;93(1105): 679-685.
43. Chalya PL, Mabula JB, Dass RM, Kabangila R, Jaka H, Mchembe MD, *et al*. Surgical management of diabetic foot ulcers: a Tanzanian university teaching hospital experience. *BMC Res Notes* 2011; 4:365.
44. Unachukwu C, Babatunde S, Ihekwaba AE. Diabetes, hand and /or foot ulcers: a cross-sectional hospital-based study in Port Harcourt, Nigeria. Diabetes Res Clin Pract 2007; 75(2):148-152.
45. Eze JN, Obikili EN, Ezepue UF, Ozoemena OF, Esom EA. Patterns of handedness and socio-cultural influences on dextrality amongst University of Nigeria Medical students. *J Expt Clin Anat* 2009; 8(2):26-30.
46. Speak K. Management of highly exuding diabetic foot ulcers. *Diabetic Foot Can* 2014;2(3): 28–33.
47. Jones V, Milton T. When and how to use iodine dressings. *Nurs Times.* 2000;96(45 Suppl):2-3.
48. Gulati S, Qureshi A, Srivastava A, Kataria K, Kumar P, Ji AB. A prospective randomized study to compare the effectiveness of honey dressing vs. povidone iodine dressing in chronic wound healing. *Indian J Surg* 2014; 76(3):193–198.

UNDER PEER REVIEW

UNDER PEER REVIEW